Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
very logical post, aphib-
and this company is gonna be a powerhouse, in due time. they are making all the right steps in building this company into becoming hugely successful. I've been steadily adding shares lately, and have been holding shares of PAOG since January 2017.
GLTU
i'm curious -is stiiilzy
a publicly traded company ?
t.i.a.
its still hard to believe-
PAOG is entering THE HOTTEST NEW INDUSTRY- CBD- an industry that will be a $ 24 BILLION DOLLAR INDUSTRY BY 2023,
and pps is still in the .002's.
BUT- not for much longer.
ERB- thanks a bunch for the pics.-
and updating us on their exhibit. big things in store for RBII/PAOG and its shareholders.
GLTU
thanks for the great pics, DOC-
much appreciated by all here. K.R. is doing everything he said he would do. his plan is all coming together for a very successful run coming.
PAOG is now in the TOP 10 MOST ACTIVE IHUB BOARDS-
we're starting to get a lil attention here.
GO PAOG $$$$$$
PAOG is definitely in the right business-
at the right time. the CBD INDUSTRY is setting up to be the fastest growing industry in the next 5 years. looking at $ 24 BILLION DOLLARS by 2023. i'm sure K.R. is well aware of that and what he is building here. the guy had OVER 9,000 AFFILIATES with OVER $ 100 MILLION DOLLARS in REVENUES with his last company. I see an explosive 4th Q coming for PAOG $$$$$
thanks for the update, DOC-
PAOG products are looking to be HOT SELLERS !
like somebody on here said, will they be able to keep
up with the demand ? now, that's a good problem to have .
the CBD INDUSTRY is set to explode. also- pressure on the FDA to do the right thing, will really pull in the big-money investors.
thanks for posting the pics, DOC-
are they really already sold out of product ?
I don't if that's good or bad ? i'd hate to have no new product available for additional customers, but it also shows the the strong demand for our products.
if they are already sold out-
that's not very good business practice. they anticipated a huge crowd, and should have prepared ? what's with the darts ?
i'm with you, aphib- and I find -
it absolutely absurd this stock is trading in the .002's !
its obvious not many people truly realize the enormity of
HUGE SALES and REVENUES that are about to hit .
the overall CBD INDUSTRY WILL BE UNPRECEDENTED !
I do think Hawaii meant that post-
as "tongue in cheek". as he's referring to the bashers who posted on here
about the previous H.T.T.C. last month.
I can't help pounding the table here-
but can somebody show me a comparable industry with year-to- year growth
over 100 % ???
PAOG HAS THE POTENTIAL TO BE MONUMENTAL !!!
The big question is: Just how big could the CBD market be?
Predictive analysis and market research company Brightfield Group believes it has the answer.
In a newly released report from Brightfield, the company is calling for year-over-year CBD product sales growth in the United States of 706% in 2019 to around $5 billion -- not a typo – and sales of $23.7 billion by 2023. Comparatively, about $620 million worth of CBD products were sold last year in the United States (based on 706% growth to $5 billion). Growing CBD revenue from about $620 million in 2018 to $23.7 billion by 2023 works out to (drum roll) a compound annual growth rate (CAGR) of a whopping 107%! Compare that to some of the most robust broad-based growth estimates for cannabis, which call for a CAGR of around 25%, and you can see why CBD is all the buzz (without creating an actual buzz) on Wall Street.
is anyone here at the show ?
please keep us posted.
T.I.A.
that would be OVER 9,000 AFFILIATES-
WITH OVER $ 100 MILLION IN REVENUES $$$$$$
now let's get those distributers lines up so we can sell
OVER $ 100 BILLION this time .
PAOG $$$$$$$
well, doo if they can keep doing -
weekend shows while selling their products ? lol. but seriously- I agree with you. what good is having product if you cannot sell it ??
let's hope KARL resolves this issue soon.
The big question is: Just how big could the CBD market be?
Predictive analysis and market research company Brightfield Group believes it has the answer.
In a newly released report from Brightfield, the company is calling for year-over-year CBD product sales growth in the United States of 706% in 2019 to around $5 billion -- not a typo – and sales of $23.7 billion by 2023. Comparatively, about $620 million worth of CBD products were sold last year in the United States (based on 706% growth to $5 billion). Growing CBD revenue from about $620 million in 2018 to $23.7 billion by 2023 works out to (drum roll) a compound annual growth rate (CAGR) of a whopping 107%! Compare that to some of the most robust broad-based growth estimates for cannabis, which call for a CAGR of around 25%, and you can see why CBD is all the buzz (without creating an actual buzz) on Wall Street.
and to think PAOG is still trading at .0025 ?, is JUST PLAIN NUTS !!!!
but not for much longer.
I guess i'm the only one here -
without F.B ,lol. it would be nice to see some pics.
doo-I have to agree-
they're gonna need distributers set up soon, if they want to sell
these awesome products. but i'm sure K.R. has them lined up.
expecting them to p.r. this very soon.
The big question is: Just how big could the CBD market be?
Predictive analysis and market research company Brightfield Group believes it has the answer.
In a newly released report from Brightfield, the company is calling for year-over-year CBD product sales growth in the United States of 706% in 2019 to around $5 billion -- not a typo – and sales of $23.7 billion by 2023. Comparatively, about $620 million worth of CBD products were sold last year in the United States (based on 706% growth to $5 billion). Growing CBD revenue from about $620 million in 2018 to $23.7 billion by 2023 works out to (drum roll) a compound annual growth rate (CAGR) of a whopping 107%! Compare that to some of the most robust broad-based growth estimates for cannabis, which call for a CAGR of around 25%, and you can see why CBD is all the buzz (without creating an actual buzz) on Wall Street.
and to think PAOG is still trading at .0025 ?, is JUST PLAIN NUTS !!!!
but not for much longer.
I do think they will have an awesome display-
and its just a glimpse of the things coming our way.
like I have been pounding the table about- the CBD INDUSTRY is gonna
be HUGE . larger than the MJ industry itself.
$ 24 BILLION by 2023 ?? K.R. is chomping at the bit to sink his teeth into this new BILLION DOLLAR business.
tick....tock.... until KA-BOOOOOM TIME !!!!
PAOG is definitely a game changing,-
once- in -a lifetime opportunity, zip-code changing stock.
AND- I am soo glad I added more shares today.
and just to think-
we have a guy like KARL RIEDEL, experienced with OVER $ 100 MILLION in REVENUES under his belt, entering this company into $ 24 BILLION DOLLAR INDUSTRY ???, well, it does give one quite the "BUZZ"!!!
EXCITING TIMES ARE AHEAD FOR US ALL HERE !!!!
GO PAOG $$$$$
CBD growth could be off the charts-
Cannabidiol is the nonpsychoactive cannabinoid that's best known for its perceived medical benefits. Since products infused with CBD don't get the user high, it has substantially broader appeal than products containing tetrahydrocannabinol (THC), the cannabinoid that gives consumers a buzz.
Further, CBD can be extracted from both the cannabis and hemp plant, whereas THC derives almost entirely from the cannabis plant, since hemp often contains very low levels of THC. Hemp plants are considerably cheaper to grow than cannabis, making hemp the preferred crop choice for CBD extraction.
The big question is: Just how big could the CBD market be?
Predictive analysis and market research company Brightfield Group believes it has the answer.
In a newly released report from Brightfield, the company is calling for year-over-year CBD product sales growth in the United States of 706% in 2019 to around $5 billion -- not a typo – and sales of $23.7 billion by 2023. Comparatively, about $620 million worth of CBD products were sold last year in the United States (based on 706% growth to $5 billion). Growing CBD revenue from about $620 million in 2018 to $23.7 billion by 2023 works out to (drum roll) a compound annual growth rate (CAGR) of a whopping 107%! Compare that to some of the most robust broad-based growth estimates for cannabis, which call for a CAGR of around 25%, and you can see why CBD is all the buzz (without creating an actual buzz) on Wall Street.
build it, and they will come...-
"Regarding PAOG, and my plans to dominate the Michigan cannabis market, I've done my best to give you all the roadmap for where we are headed.
I'm keeping alot of surprises up my sleeve regarding our MI cannabis company, because I'm excited to unveil the big surprise to shareholders. When the time is right. But I'm not letting the cat out of the bag yet. Stay tuned.
But when it comes to PAOG, and where I plan to take it, just remember...
I told you so. I'm assembling a team to accomplish these goals. You can believe in my vision, and understand that I have both a short-term and longterm strategy. Or don't. But THANK YOU to everyone who continues to support us."
- Karl Riedel | CEO
i'm still looking for-
"owc$-like " run here with PAOG.
we may not hit $ 3.20 , but a dollar cannot be ruled out.
I agree, aphib- and with-
KARL'S track record, we know he's going to deliver big-time on this company. the man pulled in OVER $ 100 MILLION in REVENUES with his last
company. and with all the hype surrounding CBD industry, you can bet
he's gonna top that $ 100 million .
GO PAOG $$$$$
BRING ON THE DETROIT H.T.C.C. !!!!
CBD MANIA is about to hit-
PAOG is primed and poised to TAKE OFF !
just look back to SEPTEMBER 2016- and see how many OTC/BB MJ STOCKS
went UP 1000 %%%%%%%%%%
anybody going to the DETROIT H.T.C.C.-
this weekend, please post some pics.
T.I.A.
GO PAOG $$$$$
KARL RIEDEL IS THE $ 100 MILLION DOLLAR + MAN ! -
$ 100 MILLION +++ IN REVENUES-
KARL REIDEL-
CEO- PAOG -" He grew the largest affiliate program in the vapor industry with over 9000 affiliates worldwide, and was responsible for generating $100MM+ in revenue for the company".
exciting times are ahead for PAOG-
KARL RIEDEL knows where he's taking this company.
he has the connections and affiliates, which we will start to see
after this weekend's DETROIT H.T.C.C.
GO PAOG $$$$$$$
new "FENDER BENDERS " will be HOT SELLERS-
Strong Demand for CBD Edibles to Create a $4.1 Billion Market by 2022
Financialnewsmedia.com News Commentary
PALM BEACH, Florida, July 24, 2019 /PRNewswire/ -- The CBD story has been on the of the most explosive to date for investors. In fact, multi-billion-dollar industries are just now being transformed by CBD, including alcohol, health and wellness, cigarettes, and the retail industry. It's impacting a range of food, too. Everything from gummy bears and cookies to candy and brownies are being infused with CBD with considerable consumer demand. Interesting to note, consumer spending on cannabis-based food and drink reached $1 billion in 2017 just in the U.S. in Canada.
"With hundreds of CBD-based products already on the market, there is clear consumer demand for CBD, and with one company already making hundreds of millions from a CBD-based drug, there is a strong financial incentive to provide clarity on the issue. More FDA guidance is expected this fall. "
you can bet the demand for PAOG's new CBD products will be
very strong. KARL RIEDEL has the connections , with OVER 9,000
affiliates with his last company.
sit back and watch as K.R. cranks up the revenues $$$$$$
Early Success Of CBD Drug Looms Large For The Industry's Future
New Frontier Data,Benzinga 7 hours ago :
By William Sumner, Hemp Business Journal Contributor
Last week, GW Pharmaceuticals (NASDAQ: GWPH) released its financial results for the second quarter, and the results surprised analysts and investors alike. Year-over-year, the company's revenue for the quarter rose from $3.3 million to $72 million, an increase of 20.8x.
Most of that revenue came from sales of the company's flagship drug, cannabidiol (CBD)-derived Epidiolex, which reached $68.4 million for the quarter and $101.9 million for the first half of the year, destroying even the most bullish of industry predictions. In context, the Hemp Business Journal's estimate last year called for 2019 Epidiolex sales to top out at $65 million (which GW Pharmaceuticals subsequently surpassed in a single quarter).
Given those results, short-term expectations are being heightened across the industry regarding consumer appetites for CBD verticals across the space.
Since Epidiolex's launch, approximately 12,000 patients have received prescriptions for the drug, and that number is expected to increase throughout the next few years. GW Pharmaceuticals is currently conducting clinical trials of Epidiolex in the treatment of tuberous sclerosis complex (TSC) in both adult and juvenile patients.
With positive results from Phase 3 trials, the company is expected to submit a supplemental new drug application (sNDA) by the end of the year. If approved, approximately 50,000 new U.S. patients could receive Epidiolex prescriptions.
The company may also add sales channels in the European market. Having last month received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) GW Pharmaceuticals expects full EMA approval in October, clearing the way for Epidyolex (the European trademark) to hit European shelves in Q4-2019. With positive results for the second quarter, GW Pharmaceuticals has seen a small surge in its stock price. In the immediate aftermath of releasing its financial results, the company's stock rose approximately 11.2%, to $169.50 per share on August 8. Since then things have leveled off somewhat, with the stock's price falling back down to around $159.38, representing an overall gain of 4.5%.
The success of Epidiolex and GW Pharmaceuticals will undoubtedly help ratchet up the pressure on the U.S. Food and Drug Administration (FDA) to issue on a ruling on CBD.
With hundreds of CBD-based products already on the market, there is clear consumer demand for CBD, and with one company already making hundreds of millions from a CBD-based drug, there is a strong financial incentive to provide clarity on the issue. More FDA guidance is expected this fall.
just check back in here another -
7 months from now, when we're over .10 cents.
CBD MAINA 2019 is ABOUT TO HIT LIKE A HURRICANE !
GO PAOG $$$$$$
aphib- i'm sorry to hear -
about your loss. CBD has many valuable uses . its just a matter of time now before the FDA changes its tune on CBD. many investors are still on the sidelines waiting for the green light.
good luck to you
bear- I could not agree more.
K.R. has a proven track record, and its just a matter of time
before he gets PAOG pulling in major revenues here.
Thousands Ask FDA to Allow CBD in Food and Supplements-
The Food and Drug Administration’s open call for public comment on CBD regulation closed last Tuesday, leaving the administration with several thousand responses to review.
At the end of May, the FDA held a public hearing on the use of CBD products, with the purpose of discussing how stakeholders and members of the public would like to see the authority regulate the products.
Over 100 speakers from a diversity of backgrounds testified at the hearing, but for those who were unable to speak or submit written testimony, the administration established a docket for public comment. Through the docket interested parties were able to submit electronic or written comments to be considered by the FDA as it considers its future policy directions on CBD products.
The initial comment period was due to close on July 2, but was extended by two weeks in light of the high number of responses from the public. By the eventual close of the comment period on July 16, the docket contained over 4,400 submissions from a mixture of individuals and organizations.
All electronic and written comments received have been made available by the FDA to view online.
Hundreds share personal experiences with CBD
Some of the most emotional comments come from individuals sharing stories of how CBD has helped them manage a variety of medical conditions, such as post-traumatic stress disorder, anxiety, and surgical pain. Others submitted comments telling of how CBD has helped them wean themselves off addictive and potentially dangerous prescription medications, like opioid painkillers.
“I have been using CBD products as part of my treatment plan to manage my autism spectrum disorder and ADHD,” wrote one respondent. “They grant me a sense of emotional stability and well-being that no prescription medication has ever been able to provide.”
“Preventing the use of CBD in dietary supplements, food, and interstate commerce makes it difficult for people to access the compound,” they continued. “Should I want to use CBD while traveling (a necessity given the distress it imposes to people on the autism spectrum), I must bring my own supply with me wherever I go. It would be not only convenient, but medically-expedient to have the option of having access to as many CBD products as possible wherever I go.”
Another commentator detailed their struggle recovering from cancer-related surgeries while also suffering from fibromyalgia and other chronic conditions.
“As a chronic pain sufferer who was taking hydrocodone on a daily basis for pain from cancer surgeries, severe fibromyalgia and arthritis as well as sufferings from severe tinnitus, I can definitely say that CBD oil has changed my life,” they wrote.
“I was very skeptical whether CBD oil would make any difference but after trying it at the urging of my oncologist I found that I [now have] another tool in fighting my chronic pain.”
“I still wake up at night with severe pain and need to take the hydrocodone, but the severity of the pain is somewhat lower and I am able to sleep longer before the pain wakes me up. All in all, I have found that the CBD oil has made quality of life much better.”
Professional associations offer statements in support of CBD supplements
Also among the submissions to the docket were a number of official statements from medical and industry organizations, recommending that CBD be regulated as a health supplement.
“Our patient community has used non-FDA approved CBD and other cannabis-based products when other options have failed to provide seizure control for their family member with Dravet syndrome,” wrote the Dravet Syndrome Foundation in their statement. “Due to reports of extreme variations in product consistency and frequent label misrepresentation, we would welcome standardized labeling for cannabis based dietary supplements and foods including concentration, ingredients, and stability.”
The National Cannabis Industry Association (NCIA) also submitted an official statement, alongside a 49-page report full of “relevant prior work” for the consideration of the FDA.
“We are grateful that FDA is accepting public comments from the CBD/hemp industry and interested parties,” wrote Andrew Kline, director of public policy, on behalf of the NCIA.
“Given the substantial interest in this topic and the need for regulations and standardization throughout the industry, [we] are providing specific insight into all facets the FDA would like to examine, including health and safety risks, manufacturing and product quality, and marketing, labeling, and sales.”
The statement was co-signed by Aaron Smith, the executive director of the NCIA, as well as by a number of other cannabis/hemp entrepreneurs, scientists, and medical professionals who are members of the NCIA and form part of a new “expert coalition” formed by the NCIA for the explicit purpose of working with the FDA to answer their questions and generally provide industry insight.
A number of other prominent organizations, including the National Association of State Departments of Agriculture (NASDA), New York State Bar Association, National Grocers Association, U.S. Hemp Roundtable, Vote Hemp, and the Center for Science in the Public Interest (CSPI) also provided comprehensive responses to the FDA’s request for information.